Biomarker Landscape of Antibody Drug Conjugates (ADCs) and Bispecific Antibodies in Clinical Trials for Lung Cancer

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2025-01-01 DOI:10.1016/j.cllc.2024.10.008

Madhan Srinivasan Kumar , Sameer Deshmukh , Charmi Bhanushali , Yanis Boumber , Johnathan Riess , Abdul Rafeh Naqash , Vivek Subbiah , Aakash Desai

{"title":"Biomarker Landscape of Antibody Drug Conjugates (ADCs) and Bispecific Antibodies in Clinical Trials for Lung Cancer","authors":"Madhan Srinivasan Kumar , Sameer Deshmukh , Charmi Bhanushali , Yanis Boumber , Johnathan Riess , Abdul Rafeh Naqash , Vivek Subbiah , Aakash Desai","doi":"10.1016/j.cllc.2024.10.008","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Lung cancer remains the leading cause of cancer-related mortality globally, highlighting the critical need for innovative treatment strategies. Despite advancements in therapy, the 5-year survival rate for lung cancer remains low at 26.7%. Novel therapeutic approaches such as antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) have shown promise in improving outcomes. ADCs offer targeted cancer cell treatment with minimal cytotoxicity to normal cells, while bsAbs can recruit T cells to tumor sites, enhancing immune response without the need for T cell receptor specificity. However, current drug development often lacks a biomarker-driven approach. The study of clinical trials reveals that while 69.6% focus on bsAbs and 30.4% on ADCs, only 47.8% incorporate biomarker testing, primarily using next-generation sequencing (NGS) and immunohistochemistry (IHC). Common targets include EGFR x c-MET and PD-1 x CTLA-4 for bsAbs, and TROP2 and HER2 for ADCs, with topoisomerase inhibitors and monomethyl auristatin E as frequent payloads. Integrating prospective biomarker strategies in future trials is crucial for advancing personalized lung cancer treatments.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"26 1","pages":"Pages e5-e10"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424002225","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

•
Lung cancer remains the leading cause of cancer-related mortality globally, highlighting the critical need for innovative treatment strategies. Despite advancements in therapy, the 5-year survival rate for lung cancer remains low at 26.7%. Novel therapeutic approaches such as antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) have shown promise in improving outcomes. ADCs offer targeted cancer cell treatment with minimal cytotoxicity to normal cells, while bsAbs can recruit T cells to tumor sites, enhancing immune response without the need for T cell receptor specificity. However, current drug development often lacks a biomarker-driven approach. The study of clinical trials reveals that while 69.6% focus on bsAbs and 30.4% on ADCs, only 47.8% incorporate biomarker testing, primarily using next-generation sequencing (NGS) and immunohistochemistry (IHC). Common targets include EGFR x c-MET and PD-1 x CTLA-4 for bsAbs, and TROP2 and HER2 for ADCs, with topoisomerase inhibitors and monomethyl auristatin E as frequent payloads. Integrating prospective biomarker strategies in future trials is crucial for advancing personalized lung cancer treatments.

查看原文本刊更多论文

肺癌临床试验中抗体药物共轭物 (ADC) 和双特异性抗体的生物标记物情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.